NVNO
enVVeno Medical Corporation [NVNO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NVNO Stock Summary
In the News
NVNO Financial details
Company Rating
-
Market Cap
66.45M
Income
-22.75M
Revenue
824K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-2.27
Forward P/E
-
PEG
2.33
P/S
-
P/B
2.07
P/C
-
P/FCF
-3.45
Quick Ratio
12.65
Current Ratio
12.91
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.95
EPS next Y
-
EPS next Q
-
EPS this Y
-11.57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-30.87%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-6.67%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-8.33%
Inst Own
-
Inst Trans
-
ROA
-81%
ROE
-72%
ROC
-0.98%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.51-6.97
52W High
+51.33%
52W Low
+354%
RSI
36
Rel Volume
0.2
Avg Volume
131.62K
Volume
26.01K
Perf Week
-18.2%
Perf Month
-15.14%
Perf Quarter
-17.3%
Perf Half Y
-27.99%
-
-
-
-
Beta
1.116
-
-
Volatility
0.91%, 0.6%
Prev Close
-3.2%
Price
9.08
Change
-9.47%
Company Profile
- Volume Average 131.62K
- Market Capitalization 66.45M
- Employee 31
- CEO Mr. Robert A. Berman
- Headquarters Irvine,CA,US
- IPO Date 2018-05-31
-
Website
https://www.envveno.com 
enVVeno Medical Corporation, a medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of severe deep venous chronic venous insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
